PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31320594-0	2019	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.	midostaurin	74-85	BCL2 apoptosis regulator	Homo sapiens	14-19	
31320594-9	2019	In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML.	midostaurin	185-196	BCL2 apoptosis regulator	Homo sapiens	123-128